“Expansion of Pharmaceutical-Grade Medical Cannabis Products”
- Pharmaceutical companies are increasingly developing standardized, high-purity medical cannabis formulations such as oils, capsules, and sublingual sprays to meet regulatory standards and ensure patient safety
- Growing investments in clinical trials for cannabis-based therapeutics targeting conditions such as epilepsy, multiple sclerosis, and chronic pain are elevating the medical credibility of cannabis products
- The introduction of prescription-only cannabis medications is improving physician confidence and driving higher patient adoption rates in regulated markets
For instance,
- In February 2025, Tilray Brands, Inc. launched a new pharmaceutical-grade CBD oil targeting neurological disorders in Europe
- In November 2024, GW Pharmaceuticals expanded clinical trials for Epidiolex in new therapeutic areas including autism spectrum disorders
- In October 2024, Aurora Cannabis Inc. introduced a GMP-certified medical cannabis capsule line in Canada
- As pharmaceutical-grade products gain traction, the medical cannabis market will see enhanced legitimacy, broader healthcare integration, and stronger patient adherence
